title: [Phosphodiesterase type 5 siRNA increases cGMP in the smooth muscle cells of human corpus cavernosum].
abstract: OBJECTIVE
  To investigate the effect of phosphodiesterase type 5 (PDE5) small interfering RNA (siRNA) on the cGMP in the smooth muscle cells of human corpus cavernosum, and to provide an experimental groundwork for the gene therapy of erectile dysfunction (ED).
  
  
  METHODS
  Small interfering RNAs targeting PDE5 gene were synthesized by using web design software provided by Ambion, three siRNAs and a control siRNA were synthesized by Ambion. siRNAs were transfected into the smooth muscle cells of human corpus cavernosum by using siPORT Lipid reagent. cGMP was detected by ELISA at different times (24, 48, 72 and 96 h) after transfection.
  
  
  RESULTS
  The cGMP levels of the siRNA1, siRNA2 and siRNA3 groups were significantly higher than those of the siRNA control and blank control groups (P < 0.05), and so was it in the siRNA1 group than the siRNA2 and siRNA3 groups (P < 0.05), with significant difference between the siRNA control and the blank control group (P > 0.05).
  
  
  CONCLUSIONS
  The synthesized siRNAs in vitro are capable of increasing the level of cGMP in the smooth muscle cells of human corpus cavernosum, different siRNAs with different capabilities. The siRNA technique could provide not only an extremely powerful tool for the functional analysis of genome but also a new approach to ED gene therapy.
authors.affiliation: Department of Urology, People's Hospital of Peking University, Beijing 100044, China.
authors.forename: Guo-qiang
authors.initials: GQ
authors.lastname: Chen
authors.forename: Wen-jun
authors.initials: WJ
authors.lastname: Bai
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Wang
authors.forename: Shi-jun
authors.initials: SJ
authors.lastname: Liu
authors.forename: Pei-ying
authors.initials: PY
authors.lastname: He
authors.forename: Shu-kun
authors.initials: SK
authors.lastname: Hou
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000235:genetics*; D002478:Cells, Cultured; D006152:Cyclic GMP / Q000378:metabolism*; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D020868:Gene Silencing; D006801:Humans; D008297:Male; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism*; D010413:Penis / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology*; D014162:Transfection
chemical_list: D034741:RNA, Small Interfering; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human; D006152:Cyclic GMP